Breaking News: Palisade Bio Successfully Closes $5 Million Public Offering Under Nasdaq Rules!

Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) —

Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $5 million prior to deducting underwriting commissions and offering expenses. The offering is comprised of (i) 158,000 Class A Units with each unit consisting of (a) one share of common stock and (b) one common warrant to purchase one share of common stock (the “Common Warrants”), and (ii) 3,120,688 Class B Units with each unit consisting of (a) one prefunded common stock purchase warrant to purchase one share of common stock (“Prefunded Warrants”) and (b) one Common Warrant. The price per Class A Unit is $1.525 and the price per Class B Unit is $1.5249 (collectively, the “Offering”).

Breaking news in the pharmaceutical industry as Palisade Bio, Inc. has successfully closed a $5 million public offering under Nasdaq rules. This significant milestone marks a new chapter for the clinical-stage biopharmaceutical company that is dedicated to developing innovative therapeutics for autoimmune, inflammatory, and fibrotic diseases. The offering, which consisted of both Class A and Class B Units, was met with great success and underscores investor confidence in the company’s mission and potential for growth.

Palisade Bio’s focus on addressing unmet medical needs in the field of autoimmune, inflammatory, and fibrotic diseases has garnered attention from investors and industry stakeholders alike. The company’s commitment to advancing novel treatments and therapies underscores its dedication to making a meaningful impact on patients’ lives and improving healthcare outcomes.

The successful closing of the public offering signifies a vote of confidence in Palisade Bio’s leadership team, research and development efforts, and overall business strategy. As the company continues to progress in its clinical programs and pipeline development, the additional funds raised through the offering will support ongoing research, clinical trials, and potential commercialization efforts.

Overall, this announcement marks a significant achievement for Palisade Bio and sets the stage for continued growth and innovation in the biopharmaceutical industry.

How This Will Effect Me

As an investor, the successful public offering by Palisade Bio may present an opportunity for potential growth and returns on investment. The company’s focus on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases indicates a promising future in the pharmaceutical industry. By closing a $5 million public offering under Nasdaq rules, Palisade Bio has demonstrated its ability to attract funding and support for its research and development efforts. This could potentially lead to advancements in treatment options for patients and drive shareholder value.

How This Will Effect the World

The successful closing of a $5 million public offering by Palisade Bio signifies a step forward in the development of innovative therapeutics for autoimmune, inflammatory, and fibrotic diseases. By securing funding to support ongoing research and clinical trials, the company is contributing to the advancement of medical science and the potential treatment options available to patients worldwide. This achievement demonstrates the importance of investing in biopharmaceutical companies that are dedicated to addressing unmet medical needs and improving healthcare outcomes on a global scale.

Conclusion

Palisade Bio’s successful $5 million public offering under Nasdaq rules marks a significant milestone for the company and the biopharmaceutical industry as a whole. The funds raised will support ongoing research and development efforts aimed at developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases. This achievement underscores investor confidence in Palisade Bio’s mission and potential for growth, highlighting the company’s commitment to making a meaningful impact on patients’ lives and advancing healthcare innovations. As the company continues to progress in its clinical programs and pipeline development, the world can expect to see continued advancements in the treatment options available for various medical conditions, ultimately leading to improved health outcomes for patients globally.